Argenx Se (ARGX) Retained Earnings (2015 - 2026)
Argenx Se (ARGX) posted quarterly Retained Earnings of $1.4 billion for Q2 2026, up 100.12% year-on-year from $702.6 million in Q2 2025, and up 10.71% on a QoQ basis from $1.3 billion in Q4 2025.
Argenx Se (ARGX) Retained Earnings (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Retained Earnings for 12 consecutive years, with $1.4 billion the latest figure, recorded in Q2 2026.
- Quarterly Retained Earnings rose 100.12% year-over-year to $1.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.4 billion (up 100.12% YoY) and the FY2025 annual result came in at $1.3 billion, up 180.8% from the prior year.
- Retained Earnings rose to $1.4 billion in Q2 2026 per ARGX's latest filing, from $1.3 billion in the prior quarter.
- Over the last five years, Retained Earnings for ARGX reached as high as $1.4 billion in Q2 2026 and fell as low as -$1157.0 billion in Q2 2025.
- A 5-year average of -$129.7 billion and a median of -$2.1 billion in 2022 frame the typical range for Retained Earnings.
- The largest YoY upside for Retained Earnings was 180.8% in 2025 against a maximum downside of 47368.16% in 2025.
- Year by year, Retained Earnings stood at -$2.1 billion in 2022, then decreased by 13.98% to -$2.4 billion in 2023, then jumped by 34.64% to -$1.6 billion in 2024, then soared by 180.8% to $1.3 billion in 2025, then climbed by 10.71% to $1.4 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $1.4 billion, $1.3 billion, and -$1157.0 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | -24.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.41 Bn |
| Dec 31, 2025 | 1.27 Bn |
| Jun 30, 2025 | -1,156.98 Bn |
| Dec 31, 2024 | -1.57 Bn |
| Jun 30, 2024 | -2.44 Bn |
| Dec 31, 2023 | -2.40 Bn |
| Jun 30, 2023 | -2.23 Bn |
| Dec 31, 2022 | -2.11 Bn |
| Jun 30, 2022 | -1.84 Bn |
| Dec 31, 2021 | -1.40 Bn |
| Jun 30, 2021 | -928.76 Mn |
| Dec 31, 2020 | -980.34 Mn |
| Jun 30, 2020 | -612.45 Mn |
| Dec 31, 2019 | -378.45 Mn |
| Jun 30, 2019 | -244.35 Mn |
| Dec 31, 2018 | -193.00 Mn |
| Jun 30, 2018 | -177.57 Mn |
| Dec 31, 2017 | -145.14 Mn |
| Jun 30, 2017 | 13.53 Mn |
| Dec 31, 2016 | -104.62 Mn |